Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
NCT07433400 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2026-02-25
Summary
The objective of this retrospective study is to examine the outcome of patients who relapse with Ph+ ALL and to potentially identify response profiles in order toadvance the treatment regimens that can be offered.
Conditions
- Ph Positive ALL
Sponsors & Collaborators
-
Group for Research in Adult Acute Lymphoblastic Leukemia
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-08-29
- Primary Completion
- 2035-12-31
- Completion
- 2035-12-31
Countries
- France
Study Locations
More Related Trials
-
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
NCT05182385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
NCT03797261 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
NCT03505554 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)
NCT03751072 ·Status: COMPLETED
-
Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia
NCT01455025 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
NCT01756118 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
NCT00878722 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
NCT02361346 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.
NCT06356922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02556346 ·Status: WITHDRAWN ·Phase: PHASE1
-
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT01466179 ·Status: COMPLETED ·Phase: PHASE2
-
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467 ·Status: RECRUITING ·Phase: PHASE2
-
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
NCT02003612 ·Status: COMPLETED
-
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
NCT07454226 ·Status: RECRUITING ·Phase: NA
-
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
NCT03740529 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients
NCT05619978 ·Status: COMPLETED
-
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
NCT05310591 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT00462761 ·Status: COMPLETED ·Phase: PHASE1
-
Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative
NCT05750706 ·Status: COMPLETED
-
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
NCT02848911 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
NCT05424380 ·Status: TERMINATED ·Phase: PHASE1
-
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
NCT06754267 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
NCT00727415 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
NCT01724177 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm
NCT04992949 ·Status: COMPLETED ·Phase: PHASE2